Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging
NCT02967458Phase 2Completed
- Sponsor
- Thomas Jefferson University
- Start
- Feb 2017
- Primary completion
- Feb 2018
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perflutren lipid microspheres in prostate cancer (PCa), sponsored by Thomas Jefferson University. Primary endpoints: Percentage of Subjects Whose Prostate Cancer Was Detected With Subharmonic Imaging at 1 week, Percentage of Biopsy Cores in Which Prostate Cancer Was Detected Using Subharmonic Imaging at 1 week and 1 more. Started Feb 2017; status: completed.
02
Drugs
perflutren lipid microspheres
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02967458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02967458.